Floatz logo

Foralumab

Non-Active Secondary Progressive Multiple Sclerosis

Tiziana Life Sciences LTDmonoclonal_antibodyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Non-Active Secondary Progressive Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Foralumab Tzls-401
Tiziana Life Sciences LTD
Phase 2CCC

Same molecule, other indications

Foralumab is also rated in:

Alzheimers DiseaseDormant
CCC
Indicative ·
53 / 100
View asset →
DementiaDormant
CCC
Indicative ·
53 / 100
View asset →
secondary progressive multiple sclerosisDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →